<DOC>
	<DOC>NCT00316719</DOC>
	<brief_summary>This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.</brief_summary>
	<brief_title>Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criteria: Have compensated chronic hepatitis B. Have not been treated with anti HBV agents with antiproliferative activity against. However, previous Interferon (IFN) therapy is permitted. Ability to read, understand, and sign the informed consent. Have a positive serum HBVDNA &gt;= 1,000,000 copies/mL and ALT level 50500 U/L Exclusion criteria: Having or suspected of having liver cancer. Coinfected with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV). Autoimmune hepatitis. Received any previous transplantation or having a plan for any transplantation. Existence of any serious complication, except hepatitis B.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>treatment naive</keyword>
	<keyword>CHB</keyword>
	<keyword>adefovir</keyword>
	<keyword>monotherapy</keyword>
</DOC>